Organization
Irvine
6 abstracts
Abstract
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.Org: City of Hope Comprehensive Cancer Center, CanSino Biologics, Flagstaff, Yale University School of Medicine, CTI BioPharma,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
Overcoming racial and ethnic disparities in clinical trial enrollment real world evidence from an NCI-Designated Cancer Center in a minority majority county.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of California Irvine, Irvine, University of California Medical Center,
Abstract
Defining low-HER2 cancers using RNA quantification by next generation sequencing.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Medical Center, NJ, Genomic Testing Cooperative, Irvine,
Abstract
Immune related adverse events (irAEs) in patients with solid tumors and advanced chronic kidney disease (CKD) receiving checkpoint inhibitors (CPIs).Org: University of California Irvine Department of Medicine, University of California Irvine, Irvine, University of California Irvine School of Medicine, University of California Irvine Medical Center,
Abstract
Multi-institutional study evaluating the role of circulating tumor DNA (ctDNA) in management of appendiceal cancers (AC).Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Section of Surgical Oncology,